AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 AFC picture-pointing paradigm
Number of subjects: 250
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-set response format in quiet
Number of subjects: 250
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental change for word recognition
Number of subjects: 250
Study 35732151 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Number of subjects: 0
Study 35732151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35732155 — intervention group
Group type: EXPERIMENTAL
Intervention: P. vivax serological markers
Number of subjects: 0
Study 35732155 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of eight P. vivax proteins
Number of subjects: 0
Study 35732222 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2-I users
Number of subjects: 324
Study 35732222 — intervention group
Group type: COMPARATOR
Intervention: Non-SGLT2-I users
Number of subjects: 324
Study 35732441 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1088
Study 35732441 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1088
Study 35732870 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Nucleoprotein assay (Abbott-N)
Number of subjects: 0
Study 35732870 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche Elecsys Nucleoprotein assay (Roche-N)
Number of subjects: 0
Study 35732870 — intervention group
Group type: EXPERIMENTAL
Intervention: MSD Spike assay
Number of subjects: 0
Study 35732870 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche Elecsys Spike assay (Roche-S)
Number of subjects: 0
Study 35732870 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche Elecsys Spike assay
Number of subjects: 0
Study 35733142 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvest for Health mentored vegetable gardening intervention
Number of subjects: 100
Study 35734087 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster COVID-19 mRNA vaccination during pregnancy
Number of subjects: 240
Study 35734087 — intervention group
Group type: COMPARATOR
Intervention: Primary 2-dose series of COVID-19 mRNA vaccination during pregnancy
Number of subjects: 240
Study 35735167 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend-oriented networks with weekly contact
Number of subjects: 0
Study 35735167 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-to-moderate networks
Number of subjects: 0
Study 35735167 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with many close confidants
Number of subjects: 0
Study 35735167 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals reporting moderately frequent contact with moderately-sized networks
Number of subjects: 0
Study 35736814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh dose-rate radiation (FLASH); single dose; specific dosage not mentioned.
Number of subjects: 0
Study 35736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant talazoparib for 8 weeks
Number of subjects: 13
Study 35736816 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant talazoparib
Number of subjects: 13
Study 35737143 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol-5D-5L (EQ-5D-5L)
Number of subjects: 0
Study 35737143 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC-QLQ-C30
Number of subjects: 0
Study 35737143 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS anxiety
Number of subjects: 0
Study 35737143 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS depression
Number of subjects: 0
Study 35737143 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL questionnaires
Number of subjects: 0
Study 35737291 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental EDOF contact lens
Number of subjects: 72
Study 35737291 — intervention group
Group type: COMPARATOR
Intervention: Single-vision control lens
Number of subjects: 72
Study 35737298 — intervention group
Group type: EXPERIMENTAL
Intervention: ddBCMA CAR T cells
Number of subjects: 0
Study 35737298 — intervention group
Group type: COMPARATOR
Intervention: BCMA-directed scFv-based C11D5.3 CAR
Number of subjects: 0
Study 35737430 — intervention group
Group type: EXPERIMENTAL
Intervention: HoloLens mixed reality headset for needle guidance
Number of subjects: 7
Study 35737443 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered behavioral weight loss intervention using an ad libitum whole food plant-based diet (WFPBD) over 12 weeks
Number of subjects: 15
Study 35737454 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVIA 2.0
Number of subjects: 234
Study 35737454 — intervention group
Group type: COMPARATOR
Intervention: LIVIA 1
Number of subjects: 234
Study 35737460 — intervention group
Group type: EXPERIMENTAL
Intervention: sNFL measurement with covariate adjustment
Number of subjects: 571
Study 35737460 — intervention group
Group type: EXPERIMENTAL
Intervention: sNFL measurement
Number of subjects: 571
Study 35737639 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011 (once per week in 28-day cycles)
Number of subjects: 69
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with cyclophosphamide and dexamethasone
Number of subjects: 35
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance after 12 cycles of treatment
Number of subjects: 35
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 35
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 35
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 35
Study 35737873 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to alternate therapy
Number of subjects: 35
Study 35737961 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered wheelchair
Number of subjects: 30
Study 35737961 — intervention group
Group type: COMPARATOR
Intervention: Simulator-based practice
Number of subjects: 30
Study 35738652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-QFR
Number of subjects: 216
Study 35738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest income quartile (Q1)
Number of subjects: 5974
Study 35738711 — intervention group
Group type: COMPARATOR
Intervention: Highest income quartile (Q4)
Number of subjects: 5974
Study 35738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level Q3
Number of subjects: 5974
Study 35738711 — intervention group
Group type: EXPERIMENTAL
Intervention: Income level Q4
Number of subjects: 5974
Study 35738745 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral cerclage ventriculoplasty
Number of subjects: 19
Study 35738747 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable valves (SEVs)
Number of subjects: 7528
Study 35738971 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 1 (previously PPV23-immunized)
Number of subjects: 129
Study 35738971 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 2 (PPV23-naïve)
Number of subjects: 129
Study 35738971 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 1
Number of subjects: 129
Study 35738971 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 immunization in Group 2
Number of subjects: 129
Study 35738971 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GMTs between Group 1 and Group 2
Number of subjects: 129
Study 35738971 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GMTs between Indigenous and non-Indigenous patients
Number of subjects: 129
Study 35738999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2mg oral daily along with TAS-102 starting at 35 mg/m
Number of subjects: 25
Study 35739094 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (3 doses)
Number of subjects: 0
Study 35739300 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (up to 8 weeks pre-surgical)
Number of subjects: 20
Study 35739539 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD-DS)
Number of subjects: 2
Study 35739539 — intervention group
Group type: COMPARATOR
Intervention: Gastric bypass or sleeve gastrectomy (RYGB + SG)
Number of subjects: 2
Study 35740079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (LDRT) 0.5 Gy
Number of subjects: 30
Study 35740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Pulmonary Embolism (PE) diagnosed in patients with venous congestion (VC)
Number of subjects: 268
Study 35740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Segments with venous congestion (VC)
Number of subjects: 268
Study 35740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous diameters in segments with AO
Number of subjects: 268
Study 35740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial diameters in segments with AO
Number of subjects: 268
Study 35740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar opacities (AO) without venous congestion (VC)
Number of subjects: 268
Study 35740433 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL eosinophilia (N = 21)
Number of subjects: 63
Study 35740433 — intervention group
Group type: COMPARATOR
Intervention: No BAL eosinophilia (N = 36)
Number of subjects: 63
Study 35740433 — intervention group
Group type: COMPARATOR
Intervention: BAL neutrophilia (N = 41 participants)
Number of subjects: 63
Study 35740433 — intervention group
Group type: COMPARATOR
Intervention: BAL lymphocytosis (N = 27 participants)
Number of subjects: 63
Study 35740433 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood eosinophilia at various thresholds (2%, N = 37; 3%, N = 27; 4%, N = 16)
Number of subjects: 63
Study 35740603 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) at 3 mg/m²
Number of subjects: 66
Study 35740603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated doses of Gemtuzumab ozogamicin (GO3)
Number of subjects: 66
Study 35740603 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAG-M (cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone)
Number of subjects: 66
Study 35740832 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention (parental education sessions, tactile and kinesthetic stimulation during NICU, home-based activity program)
Number of subjects: 48
Study 35740832 — intervention group
Group type: COMPARATOR
Intervention: Usual care based on NIDCAP-care
Number of subjects: 48
Study 35741698 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor neuron disease patients (MND)
Number of subjects: 13
Study 35742400 — intervention group
Group type: EXPERIMENTAL
Intervention: e-OTCAT program during 12 consecutive weeks since the beginning of chemotherapy
Number of subjects: 98
Study 35742400 — intervention group
Group type: COMPARATOR
Intervention: Educational handbook and usual care
Number of subjects: 98
Study 35743333 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr Kawashima's Brain Training
Number of subjects: 0
Study 35743360 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative platelet reactivity to P2Y12 inhibitors
Number of subjects: 0
Study 35743360 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35743736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab + Best Supportive Care (BSC)
Number of subjects: 0
Study 35743736 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 0
Study 35746653 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 0
Study 35746653 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Number of subjects: 0
Study 35746653 — intervention group
Group type: COMPARATOR
Intervention: Omicron-RBD
Number of subjects: 0
Study 35747193 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-112 (125 mg/m)
Number of subjects: 66
Study 35747196 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated scarves (PTS) worn for 28 days
Number of subjects: 58
Study 35747196 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 58
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma mannose-binding lectin (p-MBL) levels (≤500 µg/l) in RPL patients
Number of subjects: 267
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma mannose-binding lectin (p-MBL) levels (>3000 µg/l) in RPL patients
Number of subjects: 267
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate plasma mannose-binding lectin (p-MBL) levels (501-3000 µg/l) in RPL patients
Number of subjects: 267
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low p-MBL levels in the first pregnancy after admission
Number of subjects: 267
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal p-MBL levels before and after RPL diagnosis
Number of subjects: 267
Study 35747402 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes of RPL patients during follow-up
Number of subjects: 267
Study 35747712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab in combination with concurrent chemoradiotherapy (cCRT)
Number of subjects: 34
Study 35747751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3
Number of subjects: 0
Study 35747751 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35747850 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle cramps
Number of subjects: 334
Study 35747850 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint and muscle aches
Number of subjects: 334
Study 35747850 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle weakness
Number of subjects: 334
Study 35747889 — intervention group
Group type: EXPERIMENTAL
Intervention: 2CARE clinical trial
Number of subjects: 0
Study 35747889 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE-HD clinical trial
Number of subjects: 0
Study 35747889 — intervention group
Group type: EXPERIMENTAL
Intervention: CREST-E clinical trial
Number of subjects: 0
Study 35748318 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial studies with whole-body positron emission tomography/computed tomography (PET/CT) using oral [18F]fluoro-thia-heptadecanoic acid and dynamic PET/CT with intravenous [11C]palmitate
Number of subjects: 39
Study 35748318 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased adipose tissue DFA trapping
Number of subjects: 39
Study 35748699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran 200 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohorts 1 and 2)
Number of subjects: 16
Study 35748699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran 100 mg subcutaneously on day 1 and week 4, then every 12 weeks (cohort 1b)
Number of subjects: 16
Study 35748699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazirsiran (all cohorts)
Number of subjects: 16
Study 35748707 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ganaxolone (low, 500 mg/day; medium, 650 mg/day; high, 713 mg/day)
Number of subjects: 17
Study 35748707 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ganaxolone
Number of subjects: 17
Study 35748853 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (BNT162b2, mRNA-1273, or ChAdOx1)
Number of subjects: 0
Study 35748853 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (BNT162b2, mRNA-1273)
Number of subjects: 0
Study 35749004 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (JNJ-64007957)
Number of subjects: 0
Study 35749016 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 60
Study 35749016 — intervention group
Group type: COMPARATOR
Intervention: Binocular microscope
Number of subjects: 60
Study 35749069 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett toric formula
Number of subjects: 3
Study 35749069 — intervention group
Group type: EXPERIMENTAL
Intervention: Holladay toric formula
Number of subjects: 3
Study 35749069 — intervention group
Group type: COMPARATOR
Intervention: Generic vergence formula with zero surgically induced astigmatism
Number of subjects: 3
Study 35749216 — intervention group
Group type: EXPERIMENTAL
Intervention: Location-triggered messages
Number of subjects: 62
Study 35749216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflections on the benefits of change
Number of subjects: 62
Study 35749216 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach monitoring
Number of subjects: 62
Study 35749216 — intervention group
Group type: EXPERIMENTAL
Intervention: Household support
Number of subjects: 62
Study 35749284 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 siRNA-LNP combined with CsA and DSG
Number of subjects: 0
Study 35749284 — intervention group
Group type: COMPARATOR
Intervention: Control siRNA-LNP combined with CsA and DSG
Number of subjects: 0
Study 35749284 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 siRNA-LNP
Number of subjects: 0
Study 35749582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus (RV) positive samples
Number of subjects: 1066
Study 35749582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequenced RV samples
Number of subjects: 1066
Study 35749582 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based surveillance
Number of subjects: 1066
Study 35750354 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL-108 with weekly paclitaxel
Number of subjects: 14
Study 35750419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 12
Study 35750422 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 group (cases)
Number of subjects: 150
Study 35750422 — intervention group
Group type: COMPARATOR
Intervention: Control group (without COVID-19)
Number of subjects: 150
Study 35750559 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) during surveillance cystoscopy
Number of subjects: 181
Study 35750559 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) following TURBT
Number of subjects: 181
Study 35750559 — intervention group
Group type: COMPARATOR
Intervention: Prior exposure to HAL
Number of subjects: 181
Study 35750559 — intervention group
Group type: COMPARATOR
Intervention: No prior intravesical therapy
Number of subjects: 181
Study 35750580 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography (CAG)
Number of subjects: 69
Study 35750580 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary angiography (CAG)
Number of subjects: 69
Study 35750602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode end directed towards the patients' face (experimental group, EC)
Number of subjects: 48
Study 35750602 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48
Study 35750622 — intervention group
Group type: EXPERIMENTAL
Intervention: Concealed-needle blunt-tip device
Number of subjects: 11
Study 35750655 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) meditation program (10 minutes)
Number of subjects: 19
Study 35750695 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-5461 (G-quadruplex stabilizer)
Number of subjects: 40
Study 35750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 1-100 g in healthy volunteers
Number of subjects: 33
Study 35750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 25-100 g in oncology participants
Number of subjects: 33
Study 35750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) 100 g
Number of subjects: 33
Study 35750958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (IVC) up to 100 g
Number of subjects: 33
Study 35751082 — intervention group
Group type: EXPERIMENTAL
Intervention: COMID-P (Patient version of the complexity assessment tool)
Number of subjects: 159
Study 35751082 — intervention group
Group type: COMPARATOR
Intervention: COMID (Nurse version of the complexity assessment tool)
Number of subjects: 159
Study 35751122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) during clinic visit
Number of subjects: 0
Study 35751122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) at home with PCP encouragement
Number of subjects: 0
Study 35751122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) at home without PCP encouragement
Number of subjects: 0
Study 35751122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing screening (HS) in the PC office
Number of subjects: 0
Study 35751496 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel at 260 mg/m² combined with S-1 (80-120 mg/day, d1-14, q3w) for 6 cycles followed by 8 cycles of S-1 monotherapy
Number of subjects: 0
Study 35751496 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel at 180 mg/m²
Number of subjects: 0
Study 35751715 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention using a telehealth platform
Number of subjects: 122
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage history
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in pregnancy
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm premature rupture of membranes (PPROM)
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta previa
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Threatened miscarriage
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature rupture of membranes (PROM)
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone use
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal amniotic fluid volume
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple gestations
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 1033
Study 35751738 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroids
Number of subjects: 1033